Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37782311.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1909.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR+/HER2+ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients. See related article by Shagisultanova et al., p. 5021.
Medical subject headings
- Breast Neoplasms